Trials / Terminated
TerminatedNCT02982395
Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC
A Phase Ⅲ Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M (Docetaxel-PM) In Bacillius Calmette-Guerin Refractory Non-Muscle Invasive Bladder Cancer
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Samyang Biopharmaceuticals Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Nanoxel®M is effective in the treatment of patients with recurrent Ta and T1 who experienced treatment failure with at least one prior BCG intravesical treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nanoxel®M | Intravesical |
| DRUG | Mitomycin-C | Intravesical |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2016-12-05
- Last updated
- 2019-08-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02982395. Inclusion in this directory is not an endorsement.